Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 876

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 876
---
 period of five years (fifteen years in the case of R&D performed outside the United States). In March 2020, former President Trump signed into law the CARES Act (H.R. 748), which was further expanded with the signing of the Consolidation Appropriations Act of 2021 (H.R. 133) on December 27, 2020. The CARES Act (and December expansion) includes a variety of economic and tax relief measures intended to stimulate the economy, including loans for small businesses, payroll tax credits/ deferrals, and corporate income tax relief. Due to the Company’s history of tax loss carryforwards and full valuation allowance, the CARES Act did not have a significant effect on the income tax provision, as the corporate income tax relief was directed towards cash taxpayers. 17. Net Loss per Share The denominators used in the net loss per share computations are as follows:

| ​                                                  
 ​                                                  | ​ 
 ​ | ​ 
 ​ | Year Ended December 31, 
 2023                    |   |           |   | ​ | ​ | 2022 |   |           |   | ​ | ​ | 2021 |   |           |   | ​ 
 ​ |
|:---------------------------------------------------|:--|:--|:------------------------|:--|----------:|:--|:--|:--|:-----|:--|----------:|:--|:--|:--|:-----|:--|----------:|:--|:--|
| Basic:                                             | ​ | ​ | ​                       | ​ |         ​ | ​ | ​ | ​ | ​    | ​ |         ​ | ​ | ​ | ​ | ​    | ​ |         ​ | ​ | ​ |
| Weighted average common shares outstanding         | ​ | ​ | ​                       | ​ | 4,512,422 | ​ | ​ | ​ | ​    | ​ | 4,471,130 | ​ | ​ | ​ | ​    | ​ | 4,226,564 | ​ | ​ |
| Diluted:                                           | ​ | ​ | ​                       | ​ |         ​ | ​ | ​ | ​ | ​    | ​ |         ​ | ​ | ​ | ​ | ​    | ​ |         ​ | ​ | ​ |
| Weighted average common shares outstanding – Basic | ​ | ​ | ​                       | ​ | 4,512,422 | ​ |